If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
62
results.
Updated on
11/09/2025 [07:31:00]
Absstract of: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Absstract of: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Absstract of: WO2025181335A1
The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.
Absstract of: AU2025220690A1
A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and 5 homocysteine, independently in one or more samples obtained from the subject. A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and 5 homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject. ug m e t h o d f o r i d e n t i f y i n g p r e - d i s p o s i t i o n t o c o g n i t i v e d e c l i n e i n a s u b j e c t , t h e m e t h o d u g c o m p r i s i n g d e t e r m i n i n g l e v e l s o f : ( a ) o m e g a - f a t t y a c i d s , a n d v i t a m i n o r a m e t a b o l i t e t h e r e o f ; ( b ) o m e g a - f a t t y a c i d s , a n d h o m o c y s t e i n e ; ( c ) v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e ; o r ( d ) o m e g a - f a t t y a c i d s , v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e , i n d e p e n d e n t l
Absstract of: US2025277799A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Absstract of: US2025277798A1
The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.
Absstract of: US2025277268A1
Embodiments of the present disclosure herein relate to a method for providing information for predicting a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition, based on European population data. In an embodiment, the method makes it possible to accurately predict a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition by using only at least 11 single-nucleotide polymorphisms, and the ability to predict the risk groups is further enhanced when up to and at most 39 additional single-nucleotide polymorphisms are used.
Absstract of: WO2025182761A1
Provided is a method for detecting GFAP in a sample by immunoassay, the method including a first step for forming a complex of a first antibody and GFAP, and a second step for forming a complex of a second antibody and GFAP, the first antibody binding to a region consisting of amino acids at positions 111 to 115 in the amino acid sequence of GFAP.
Absstract of: KR20250129282A
본 발명은 루이소체병의 증상을 동반한 알츠하이머병 환자를 정상대조군과 구분하여 진단할 수 있는 영상 바이오 마커에 관한 것으로, 보다 상세하게는, 본 발명은 중뇌 흑색질의 도파민 운반체 섭취율(DAT-SN), 및 선조체 조가비핵의 조기 도파민 섭취율 대 지연 도파민 섭취율의 비율(E/D-PP)을 영상 바이오마커로 사용하여 정상대조군과 구별하여 루이소체병의 증상을 동반한 알츠하이머병 환자의 진단 정확도를 높이는 효과를 제공한다.
Absstract of: JP2024147610A
To provide antibodies for use in the treatment of neurodegenerative diseases, or pharmaceutical compositions thereof.SOLUTION: The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.SELECTED DRAWING: None
Absstract of: US2025268952A1
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
Absstract of: US2025270618A1
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
Absstract of: US2025271453A1
A protein antigen combination containing SERF2 and applications thereof in the field of biological detection are disclosed. The antigen combination for detecting autoantibodies can distinguish Alzheimer's disease (AD) from frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB), and the antigen combination at least includes protein fragments of SERF2. The new protein antigen composition can not only effectively identify patients with AD, but also effectively distinguish AD from FTD and DLB, enabling accurate identification of AD. It is of great importance in terms of diagnostic applications and research.
Absstract of: US2025268982A1
Non-aggregating protein analogues of proteins involved in a proteinopathy, for example Alzheimer's disease, are provided. The protein has a beta-sheet aggregation domain, and the non-aggregating protein analogue has a beta-sheet destabilizing modification in the beta-sheet aggregation domain but substantially retains wild type protein function. The beta-sheet destabilizing modification can be a substitution of a naturally occurring amino acid for a non-naturally occurring amino acid. Methods of treating a proteinopathy using the non-aggregating protein analogues and methods of designing a non-aggregating protein analogue are provided.
Absstract of: US2025270301A1
The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.
Absstract of: WO2025179300A1
Methods, compositions, and kits are capable of detecting, identifying, diagnosing, prognosing, assessing, monitoring, and/or treating a neurological injury such as acute TBI and distinguishing geriatric TBI from conditions such as dementia, Alzheimer's Disease, Parkinson's disease and the like. Also disclosed are methods of testing elderly patients who have or are suspected of having traumatic brain injury using panels of biomarkers that distinguish TBI from dementia, and, optionally, treating such patients for TBI or dementia based upon the results of the biomarker tests.
Absstract of: CN119998661A
In a first aspect, the present invention relates to a method for identifying a subject suffering from or at risk of developing Alzheimer's dementia (AD), the method comprising: (a) determining in a first bodily fluid sample of the subject at least an amount of a compound having a mass of 110.0367 in grams/mole; (b) determining an amount of the same compound as in (a) in a second body fluid sample of the subject; (c) determining a change in the amount of the compound determined according to (a) compared to the corresponding amount of the compound determined according to (b); (d) analyzing the change determined in (c) using a computer-implemented prediction algorithm capable of predicting AD in the subject based on the compound, thereby identifying a subject having AD or at risk of developing Alzheimer's dementia if AD is predicted; wherein the first body fluid sample is obtained prior to administration of thietherazine or a pharmaceutically acceptable salt thereof, and the second body fluid sample is obtained after administration of thietherazine or a pharmaceutically acceptable salt thereof to the subject.
Absstract of: US2025262247A1
The disclosure provides methods and compositions related to microglial cell development and therapies in neuronal development.
Absstract of: US2025264482A1
The present specification discloses a composition, a system, and a method for predicting or diagnosing Alzheimer's disease, comprising a detecting agent of a B cell receptor clonotype specific to an Alzheimer's disease patient, and the composition according to one aspect of the present invention has an excellent effect in predicting or diagnosing Alzheimer's disease by simply using peripheral blood mononuclear cells isolated from a subject, in addition to methods such as MRI and PET scans using radioactive substances, by comprising a detecting agent of a B cell receptor (BCR) clonotype specific to an Alzheimer's disease patient.
Absstract of: US2025262337A1
A method for detecting soluble oligomeric amyloid β in a subject is provided.
Absstract of: CN119768689A
Use of a novel highly toxic amyloid oligomer A beta o * 3F as a target for diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), A beta o * 3F is specifically bound by a 3F antibody, and exists in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD.
Absstract of: WO2025166920A1
The present invention belongs to the technical field of detection reagents, and relates to a modified polypeptide and the use thereof. The modified β amyloid protein polypeptide comprises peptide fragment I, peptide fragment II, and peptide fragment III located between the peptide fragment I and the peptide fragment II. The peptide fragment I contains a sequence as shown in SEQ ID NO: 9, the peptide fragment II contains a sequence as shown in SEQ ID NO: 18, and the peptide fragment III is composed of non-hydrophobic amino acids. Linker compounds are added between the peptide fragment I and the peptide fragment III, as well as between the peptide fragment II and the peptide fragment III. Compared with the original polypeptide, the modified polypeptide is reduced in terms of synthesis difficulty and cost, and improved in terms of stability. In terms of reaction activity with antibodies, the modified form is consistent with the original polypeptide, is a better raw material form for a calibrator of a diagnostic reagent, and is beneficial to development and wide application of a detection kit.
Absstract of: US2025257318A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
Absstract of: US2025258184A1
The present disclosure belongs to the field of biological detection, and particularly relates to a protein antigen combination for detection of Alzheimer's disease (AD) and application thereof. The specific technical solution is as follows: An antigen combination is provided, wherein the antigen combination at least simultaneously includes the following proteins: DOC2A, LGALS1, KDM4D, and ADARB1. The present disclosure provides several new protein antigens and the combination thereof, which can be used for early-screening detection or diagnosis of AD, and are particularly suitable for risk assessment and prediction prior to the onset of AD. Meanwhile, the protein antigens and the combination thereof can distinguish AD from other types of dementia, and can be further prepared into related reagents or kits according to needs.
Nº publicación: US2025257124A1 14/08/2025
Applicant:
H LUNDBECK AS [DK]
H. Lundbeck A/S
Absstract of: US2025257124A1
The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
BOPI
Electronic site
